Current Research
HeadMinder tests are being used clinically, in research investigations, and in clinical trials (Phases II, III, and IV) by pharmaceutical companies, hospitals, and large universities across several continents. Diagnostic indications include several types of non-CNS cancers, Mild Cognitive Impairment, Early-stage Dementia, Cardio-pulmonary illnesses, Multiple Sclerosis, Mild to Severe Traumatic Brain Injury, Schizophrenia, Severe Mood Disorders, Sleep Disorders, and HIV.

HeadMinder test batteries are ideally suited for multi-site trials, longitudinal research, and clinical trials in which cognitive functioning is a variable of interest. Possible applications include:

Pharmaceutical Agents
•	Detect primary CNS effects of new products
•	Detect cognitive side effects in agents with secondary CNS effects
•	Assess duration of side effects in agents (e.g., vaccinations) that have transient effects on cognitive functioning

Oncology
•	Detect onset of chemo brain symptoms and assess response to treatment

Anesthesiology
•	Compare recovery curves for different types/dosages of anesthesia
•	Evaluate impact of interventions designed to speed recovery from anesthesia

Endocrinology
•	Monitor impact of Type I and Type II Diabetes on CNS function over time
•	Monitor recovery from hyperthyroidism

Traumatic Brain Injury / Concussion
•	Monitor recovery in multiple domains of cognitive functioning with a single tool

Alzheimer's/MCI
•	Screen patients for inclusion in trials
•	Assess significance of responses indicating a lack of expected decline

Multiple Sclerosis
•	Evaluate cognitive stability in patients remotely

HIV/AIDS
•	Monitor stability in cognitive functioning over time, using each patient as his/her own control.

Schizophrenia
•	Evaluate impact of interventions targeted at improving negative symptoms of schizophrenia

Mood Disorders
•	Objectively compare response to antidepressant medication in severe depressive disorders
•	Evaluate work-readiness in persons with chronic dysphoric mood

Cardiology
•	Assess decline and recovery in cognitive functioning following cardiopulmonary bypass surgery
•	Assess impact of stent procedures in minimizing cognitive compromise
•	Assess impact of pharmaceutical treatments for hypertension and other vascular disorders in reversing cognitive deficits.

AD/HD
•	Titrate stimulant doses based on objective performance data

Chemical/Toxic Exposure
•	Assess decline and recovery after single high-dose episode
•	Detect significant decline across chronic low-dose exposure

Sleep Disorders
•	Monitor efficacy of CPAP, surgical interventions for apnea
•	Monitor variability of efficacy of vigilance promoting agents
•	Monitor side-effects (or absence of side-effects) of sleep promoting agents

Pulmonary Disorders
•	Monitor effects of hypoxemia in COPD or Asthma, and improvement following treatment

Liver/Renal Disease
•	Evaluate impact of pharmacotherapies in individuals with liver disease
•	Monitor and compare cognitive side-effect profiles of immunosuppressants following organ transplantation